Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Trial Title: Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

NCT ID: NCT05624099

Condition: Esophageal Neoplasms
Esophageal Diseases
Digestive System Neoplasms

Conditions: Official terms:
Neoplasms
Esophageal Neoplasms
Digestive System Neoplasms
Gastrointestinal Neoplasms
Esophageal Diseases
Paclitaxel

Conditions: Keywords:
Immunotherapy
Platinum
radiotherapy
Paclitaxel

Study type: Interventional

Study phase: Phase 2

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: camrelizumab
Description: 200mg intravenous drip d1q3w
Arm group label: drug

Intervention type: Drug
Intervention name: Paclitaxel drugs
Description: 150mg/m2 d1 q3w
Arm group label: drug

Intervention type: Drug
Intervention name: Platinum drug
Description: Cisplatin, carboplatin, nedaplatin and other platinum drugs
Arm group label: drug

Intervention type: Radiation
Intervention name: Radiation
Description: Dose: 5040cGy/28f
Arm group label: drug

Summary: This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Sign written informed consent and voluntarily participate in this study; 2. Patients with esophageal squamous cell carcinoma confirmed by histopathology and/or immunohistochemistry (8th edition 2017) had UICC/AJCC TNM stage IVA or oligometastatic stage IVB; 3. Survival is expected to exceed 3 months 4. Age 18-75; 5. ECOG PS 0-2 6. Never received any systemic anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, targeted and immunotherapy; 7. Have at least one measurable lesion 8. Normal function of major organs, including: 1. Routine blood test (no blood components, cell growth factors, whitening drugs, platelet raising drugs, and anemia correcting drugs are allowed within 14 days before the first use of study drugs) White blood cell count ≥ 3.0×10^9/L Neutrophil count ≥ 1.0×10^9/L Platelet count ≥ 80×109/L Hemoglobin ≥ 80 g/L 2. Blood biochemical examination: Total bilirubin ≤ 1.5×ULN ALT ≤2.5×ULN, AST ≤2.5×ULN, Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 45mL/min 9. Subjects have good compliance and cooperate with follow-up Exclusion Criteria: 1. The presence of uncontrollable pleural effusion, pericardial effusion or ascites that require repeated drainage; 2. Poor nutritional status, BMI < 18.5 Kg/m^2; If symptomatic nutritional support was corrected before randomization, enrollment could be considered after evaluation by the principal investigator; 3. Gastrointestinal bleeding (bleeding volume > 200ml/ day); 4. Patients with deep ulcers as determined by the investigator; 5. Previous allergy to monoclonal antibodies, any component of camrelizumab, paclitaxel, cisplatin or other platinum-based drugs; 6. Has received or is receiving any of the following medical treatment: 1. any radiation, chemotherapy or other antitumor drugs for the tumor; 2. Being treated with immunosuppressive agents or systemic hormones for immunosuppression purposes (dose >10mg/ day prednisone or equivalent) within 2 weeks prior to the first use of the study drug; In the absence of active autoimmune disease, inhaled or topical steroids and adrenocorticosteroid replacement at a dose of >10mg/ day or its equivalent are permitted; 3. Received live attenuated vaccine within 4 weeks before the first administration of the study drug; 4. Major surgery or severe trauma within 4 weeks before the first use of the study drug; 7. A history of any active autoimmune disease or autoimmune disease, including but not limited to: interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (which may be considered for inclusion after hormone replacement therapy); Patients with complete remission of psoriasis or childhood asthma/allergies who did not require any intervention as adults were considered for inclusion, but patients requiring medical intervention with bronchodilators were not included; 8. A history of immunodeficiency, including being HIV positive, or suffering from another acquired or congenital immunodeficiency disease, or a history of organ transplantation or allogeneic bone marrow transplantation; 9. The presence of poorly controlled cardiac clinical symptoms or diseases, including but not limited to: Such as (1) NYHAII grade or above heart failure; (2) unstable angina pectoris; (3) myocardial infarction occurred within 1 year; (4) Clinically significant supraventricular or ventricular arrhythmias are not well controlled without clinical intervention or after clinical intervention; 10. Severe infection (CTCAE > 2) occurred within 4 weeks before the first use of the study drug, such as severe pneumonia, bacteremia, infection complications requiring hospitalization; Baseline chest imaging examination indicated active pulmonary inflammation, signs and symptoms of infection within 14 days before the first use of study drugs, or the need for oral or intravenous antibiotic treatment, except for prophylactic antibiotic use; 11. Patients with active pulmonary tuberculosis infection found by medical history or CT examination, or with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or with a history of active pulmonary tuberculosis infection more than 1 year ago but without regular treatment; 12. The presence of active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL) and hepatitis C (HCV antibody positive and HCV RNA above the assay limit); 13. In the judgment of the investigator, there are other factors that may lead to the forced termination of the study, such as the presence of other serious medical conditions (including mental illness) requiring concomitant treatment, alcoholism, substance abuse, family or social factors, and factors that may affect the safety or compliance of the subjects.

Gender: All

Minimum age: 18 Years

Maximum age: 75 Years

Healthy volunteers: No

Locations:

Facility:
Name: Fujian Cancer Hospital

Address:
City: Fuzhou
Country: China

Status: Recruiting

Start date: August 1, 2023

Completion date: December 31, 2027

Lead sponsor:
Agency: Fujian Cancer Hospital
Agency class: Other

Source: Fujian Cancer Hospital

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05624099